Clinical Trial Detail

NCT ID NCT01791478
Title BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Vanderbilt-Ingram Cancer Center
Indications

Her2-receptor negative breast cancer

Therapies

Letrozole + BYL719

Age Groups: adult

Additional content available in CKB BOOST